CUAMC
CCCC icon

China Universal Asset Management Company’s C4 Therapeutics CCCC Stock Holding History

China Universal Asset Management Company’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$82.2K Buy
17,597
+281
+2% +$961 ﹤0.01% 430
2026
Q1 		$45.5K Buy
17,316
+1,524
+10% +$3.59K ﹤0.01% 462
2025
Q4 		$30.2K Buy
15,792
+3,317
+27% +$7.86K ﹤0.01% 476
2025
Q3 		$27.7K Sell
12,475
-1,786
-13% -$4.29K ﹤0.01% 451
2025
Q2 		$20.4K Buy
14,261
+22
+0.2% +$32 ﹤0.01% 451
2025
Q1 		$22.8K Sell
14,239
-728
-5% -$2.17K ﹤0.01% 455
2024
Q4 		$53.9K Buy
+14,967
New +$74.4K 0.01% 448
2023
Q4 		– Sell
-1,269
Closed -$2.36K – 436
2023
Q3 		$2.36K Buy
1,269
+626
+97% +$1.91K ﹤0.01% 426
2023
Q2 		$1.77K Sell
643
-22
-3% -$71 ﹤0.01% 434
2023
Q1 		$2.09K Buy
665
+168
+34% +$989 ﹤0.01% 430
2022
Q4 		$2.93K Buy
497
+39
+9% +$323 ﹤0.01% 346
2022
Q3 		$4K Buy
+458
New +$4.75K ﹤0.01% 292

Other funds holding CCCC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $646M AUM 291.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

China Universal Asset Management Company's CCCC Position: Q2 2026 in Review

China Universal Asset Management Company increased its C4 Therapeutics (CCCC) stake by 1.6% in Q2 2026, buying an estimated $961 and bringing the position to 17,597 shares worth $82.2K. The position accounts for ﹤0.01% of the portfolio, ranked #430.

China Universal Asset Management Company first reported a position in CCCC in Q3 2022 and has held it in 12 quarters since. 63 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • China Universal Asset Management Company held 17,597 shares of C4 Therapeutics worth $82.2K as of Q2 2026.
  • China Universal Asset Management Company bought 281 C4 Therapeutics shares in Q2 2026, an estimated $961.
  • C4 Therapeutics made up ﹤0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #430 holding.
  • China Universal Asset Management Company first reported a position in C4 Therapeutics in Q3 2022 and has held it in 12 quarters since.
  • 63 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.